Volume 63 2005

Advances in Targeted Cancer Therapy

ISBN: 978-3-7643-7174-6 (Print) 978-3-7643-7414-3 (Online)

Table of contents (11 chapters)

  1. No Access

    Book Chapter

    Pages 1-17

    Dawn of a new era in molecular cancer therapeutics

  2. No Access

    Book Chapter

    Pages 19-41

    Obtacles and opportunities in the clinical development of targeted therapeutics

  3. No Access

    Book Chapter

    Pages 43-66

    Tumor models for preclinical development of targeted agents

  4. No Access

    Book Chapter

    Pages 67-91

    Angiogenesis inhibitors: What is the clinical future?

  5. No Access

    Book Chapter

    Pages 93-115

    Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy

  6. No Access

    Book Chapter

    Pages 115-145

    Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development

  7. No Access

    Book Chapter

    Pages 147-191

    Targeted histone deacetylase inhibition for cancer prevention and therapy

  8. No Access

    Book Chapter

    Pages 183-206

    Inhibitors of cyclin-dependent kinase modulators for cancer therapy

  9. No Access

    Book Chapter

    Pages 207-225

    Targeting cyclooxygenase-2 for cancer prevention and treatment

  10. No Access

    Book Chapter

    Pages 227-274

    Antisense approaches in drug discovery and development

  11. No Access

    Book Chapter

    Pages 275-300

    Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate